HUMAN PAPILLOMAVIRUS REACTIVATION

HUMAN PAPILLOMAVIRUS REACTIVATION was reported 13 times

HUMAN PAPILLOMAVIRUS REACTIVATION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD38-directed Cytolytic Antibody [EPC] 7 0.0012
1 Proteasome Inhibitor [EPC] 7 0.0001
2 Interleukin-23 Antagonist [EPC] 2 0.0000
3 Janus Kinase Inhibitor [EPC] 2 0.0000
4 Integrin Receptor Antagonist [EPC] 1 0.0000
5 Purine Antimetabolite [EPC] 1 0.0000
6 Corticosteroid [EPC] 9 0.0000